Crohn’s Disease Treatment Market to surpass US$ 15.17 Bn by 2030
![]() |
| Crohns Disease Treatment Market |
Crohn's disease is a type of
inflammatory bowel disease (IBD) that is characterised by a chronic
inflammatory condition of the gastrointestinal tract that results in digestive
tract inflammation. The disease is limited to the large intestine's colon and
the small intestine's ileum. The disease is frequently painful and
debilitating, and in some cases can result in life-threatening complications.
Complications may include one or more of the following: bowel obstruction,
fistulas, ulcers, anal fissures, colon cancer, and other health issues. Factors
such as stress, diet, heredity, and immune system malfunction can all
contribute to Crohn's disease. The disease can strike anyone at any age.
However, the majority of people will develop it at a young age.
The rising prevalence of
inflammatory bowel diseases is expected to propel the crohn's disease treatment
market forward. Factors such as an increase in the number of inflammatory bowel
diseases (IBD) and an increase in the number of Crohn's disease patients are
expected to significantly contribute to the growth of the Crohn's disease
treatment market. For example, in May 2021, an illness-death model based on
available data was established to project the future prevalence of IBD in Asia,
and Iran in particular, from 2017 to 2035, according to an article published in
the Journal BMC Gastroenterology.
Global Crohns
Disease Treatment Market is estimated to be valued at US$ 10.92
billion in 2022 and is expected to exhibit a CAGR of 4.2% during the forecast
period (2022-2030)
According to the findings, the
study predicted a 2.5-fold increase in prevalence for Iran with 69 thousand
cases, a 2.3-fold increase for North Africa and the Middle East with 220
thousand cases, a quadrupling of the prevalence for India with 2.2 million
cases, a 1.5-fold increase for East Asia with 4.5 million cases, and a 1.6-fold
increase for high-income Asia Pacific and Southeast Asia regions with 183 and
199 thousand cases, respectively, in 2035.
The development of new and
effective therapy options to treat Crohn's disease symptoms is also an
important factor contributing to the growth of the Crohn's disease treatment
market. For example, at the Crohn's & Colitis Congress in January 2018,
researchers from the University of Washington Medicine presented a study that
developed an antibiotic that showed a fourfold better response on intestine
inflammation among Crohn's disease patients when compared to existing therapies
on the market.
Because of the disease
exacerbation caused by the COVID-19 pandemic, the COVID-19 pandemic had a
significant impact on the crohn's disease treatment market. For example,
according to an article published in December 2021 by Frontiers Media S.A., a
questionnaire survey on patients with Inflammatory Bowel Disease (IBD) was
conducted from June 16 to August 21, 2020, during their regular follow-up at a
hospital in Japan. According to the findings, 241 patients with ulcerative
colitis (UC) and 210 patients with Crohn's disease (CD) completed the survey,
with 82 (34%) and 97 (46%) reporting disease exacerbation within 2 months of
the lockdown, respectively.

Comments
Post a Comment